Breast Cancer - Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-04-05

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Anthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer. In recent days, however, agents such as Sanofi-Aventis's Taxotere and AstraZeneca's Arimidex have been gaining prominence. This report examines the current treatment paradigms for early-stage breast cancer, based on primary research data from 180 physicians in the seven major markets.


Scope

  • Analysis of current treatment practices for early-stage breast cancer based on primary research from 180 physicians in the seven major markets
  • Extent of use of antihormonal agents, such as anti-estrogens and aromatase inhibitors, in local and locally-advanced breast cancer
  • Physician awareness and ratings of late-stage pipeline drugs for breast cancer, including recently launched APP's Abraxane and GSK's lapatinib
  • Coverage of adjuvant and neoadjuvant chemotherapy in early-stage breast cancer, including the commonly used regimens in each setting


    • Report Highlights
    Sanofi-Aventis's Taxotere (docetaxel) is likely to see a significant increase in its use as adjuvant and neoadjuvant therapies in combination with anthracycline-based regimens. However, Sanofi-Aventis will need to disseminate relevant trial results to physicians to compete with the likes of paclitaxel, especially in the US.

    AstraZeneca's Arimidex (anastrozole) will replace tamoxifen as the gold-standard adjuvant therapy for local and locally advanced breast cancer, given the latest ATAC trial results in December 2004.

    Abraxane (albumin-bound paclitaxel) had the highest awareness rate among late-stage pipeline drugs, as well as being considered the most promising agent. Its recent launch and potential success in metastatic disease is likely to be translated into the adjuvant and neoadjuvant settings.


    Reasons to Purchase

  • Identify the key chemotherapy regimens in the neoadjuvant and adjuvant settings for local and locally-advanced breast cancer
  • Target physicians effectively through an understanding of prescribing behavior for antihormonal agents in pre- and postmenopausal breast cancer
  • Evaluate product potential by assessing physician awareness and rating of key late-stage pipeline drugs for breast cancer

    • Table of Contents

    Other users found this report page using the following search terms: breast cancer breast cancer treatment france germany advanced locally treatments standard stage

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.